- Porton Pharma Solutions and Dragon Sail Pharmaceutical signed a strategic partnership to advance the development, production, and supply chain integration of antibody-drug conjugates (ADC).
- The collaboration will create a one-stop service platform for ADC drugs, accelerating timelines and boosting competitiveness.
Porton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO), has partnered with Dragon Sail Pharmaceutical to integrate resources and expertise in ADC development. The agreement, signed in Guilin, China, brings together Porton’s advanced technology platforms in ADC drug product filling and Dragon Sail’s strong capabilities in biologics such as monoclonal and bispecific antibodies.
This partnership aims to establish a comprehensive service platform for ADCs, covering every stage from bulk drug substances to commercial production. The collaboration is expected to shorten development timelines and enhance delivery capabilities, benefiting global clients with reliable CMC solutions for ADC drugs.
Porton’s Chairman and CEO, Oliver (Nianfeng) Ju, highlighted the partnership’s importance, stating that it strengthens competitiveness and supports pharmaceutical innovation globally. Similarly, Guilin Sanjin’s Chairman, Zou Xun, described the alliance as a milestone in advancing ADC drug development.
By leveraging facilities in Shanghai Waigaoqiao and Lingang, the companies plan to foster a sustainable pharmaceutical ecosystem, prioritising innovation and efficiency to drive growth in the ADC sector.
